medigraphic.com
ISSN 0016-3813 (Print)

2013, Number 3

<< Back Next >>

Gac Med Mex 2013; 149 (3)

Epidemiology of bullous pemphigoid in 32 years

Solís-Arias MP, Rodríguez-Gutiérrez G, Rodríguez-Carreón AA, Vega-Memije E, Domínguez-Soto L

Language: Spanish
References: 36
Page: 344-348
PDF size: 81.45 Kb.


ABSTRACT

Objective: there are few epidemiological data of bullous pemphigoid in Latin America. The aim of this study was to identify the frequency and clinical characteristics of bullous pemphigoid in the Mexico City, General Hospital Dr. Manuel Gea González, and compare this with international reports. Materials and methods: we conducted a retrospective analysis of patients from the Department of Dermatology in Mexico City, General Hospital Dr. Manuel Gea González, between January 1979 and December 2011. We included patients with a clinical and/or histological diagnosis of bullous pemphigoid recording age, sex, direct immunofluorescence, and associated diseases. Results: a total of 42 patients diagnosed with bullous pemphigoid were found, of which 55% were women. Two thirds of patients were over 60 years of age. The most common associated diseases were diabetes mellitus, hypertension and neurological disorders. The incidence has tripled in the last decade. In the group of blistering diseases, bullous pemphigoid ranked second in frequency with 22% of patients. Conclusions: our findings are similar to those reported in the literature, but differs being pemphigus vulgaris the most frequent in the group of autoimmune blistering diseases.


REFERENCES

  1. Schmidt E, Della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin. 2011;29(3):427-38, viii-ix.

  2. Langan SM, Smeeth L. Bullous pemphigoid and pemphigus vulgaris – Incidence and mortality in the UK: population based cohort study. Br Medical J. 2008;337:a180.

  3. Baican A, Chiriac G. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Int J Dermatol. 2010;49(7):768-74.

  4. Korman NJ. Bullous pemphigoid: the latest in diagnosis, prognosis, and therapy. Arch Dermatol. 1998;134:1137-41.

  5. Gudi VS, White MI, Cruickshank N, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-East Scotland. Br J Dermatol. 2005;153:424-7.

  6. Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7:434-40.

  7. Bernard P, Vaillant L, Labeille B. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995; 131(1):48-52.

  8. Nanda A, Dvorak R, Al-Saeed K, Al-Sabah H, Alsaleh QA. Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol. 2004;43(12): 876-81.

  9. Wong SN, Chua SH. Bullous pemphigoid seen at the National Skin Centre: a 2-year retrospective review. Ann Acad Med Singapore. 2002;31:170-4.

  10. Adam BA. Bullous diseases in Malaysia: epidemiology and natural history. Int J Dermatol. 1992;31:42-5.

  11. Kulthanan K, Chularojanamontri L. Prevalence and clinical features of Thai patients with bullous pemphigoid. Asian Pac J Allergy Immunol. 2011;29(1):66-72.

  12. Clínica de enfermedades ampollosas. Centro dermatológico Pascua. http://www.facmed.unam.mx/pascua/consult4.htm.

  13. Parker SR, MacKelfresh J. Autoimmune blistering diseases in the elderly. Dermatol Clin. 2011;29(1):69-79.

  14. Jung M, Kippes W, Messer G. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266-8.

  15. Marazza G, Pham HC, Scharer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009;161:861-8.

  16. Bourdon-Lanoy E, Roujeau JC. Bullous pemphigoid in young patients: a retrospective study of 74 cases. Ann Dermatol Venereol. 2005;132(2):115-22.

  17. Swerlick RA, Korman NJ. Bullous pemphigoid: what is the prognosis? J Invest Dermatol. 2004;122.

  18. Rzany B, Partscht K. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002;138(7):903-8.

  19. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-7.

  20. Cortés B, Marazza G, Naldi L. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol. 2011.

  21. Parker SR, Dyson S. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol. 2008;59(4):582-8.

  22. Jedlickova H, Hlubinka M. Bullous pemphigoid and internal diseases – A case-control study. Eur J Dermatol. 2010;20(1):96-101. Epub 2009 Oct 2.

  23. Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011;131(3):631-6.

  24. Chen J, Li L, Chen J, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology. 2011;57(3):211-6.

  25. Tirado-Sánchez A, Montes-de-Oca G. Coexistence of bullous pemphigoid, vitiligo, and thyroid disease: a multiple autoimmune syndrome? Dermatol Online J. 2005;11(2):20.

  26. Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol. 2011;131:637-43.

  27. Marcet B, Sibaud V, Geniaux M, Taieb A. Bullous pemphigoid, primary biliary cirrhosis and vitiligo: a multiple autoimmune syndrome? Ann Med Intern. 2002;153(5):349-50.

  28. Pasic A, Ljubojevic S, Lipozencic J, Marinovic B, Loncaric D. Coexistence of psoriasis vulgaris, bullous pemphigoid and vitiligo: a case report. J Eur Acad Dermatol Venereol. 2002;16(4):426-7.

  29. Deguchi M, Tsunoda T, Tagami H. Resolution of bullous pemphigoid and improvement of vitiligo after successful treatment of squamous cell carcinoma of the skin. Clin Exp Dermatol. 1999;24(1):14-5.

  30. Arakawa M, Dainichi T, Ishii N, et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp Dermatol. 2011;20:1022-4.

  31. Tirado-Sánchez A, Díaz-Molina V, Ponce-Olivera RM. Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid. Allergol Immunopathol (Madr). 2012;40(3):152-5. doi:10.1016/j.aller.2010.12.009. Epub 2011 Apr 14.

  32. Castellano Suárez JL. Gingival disorders of immune origin. Med Oral. 2002;7(4):271-83.

  33. Van den Bergh F, Eliason SL, Giudice GJ. Type XVII collagen (BP180) can function as a cell-matrix adhesion molecule via binding to laminin 332. Matrix Biol. 2011;30(2):100-8.

  34. Steiner-Champliaud MF, Schneider Y, Favre B, et al. BPAG1 isoform-b: complex distribution pattern in striated and heart muscle and association with plectin and alpha-actinin. Exp Cell Res. 2010;316(3):297-313.

  35. Claudepierre T, Manglapus MK, Marengi N, et al. Collagen XVII and BPAG1 expression in the retina: evidence for an anchoring complex in the central nervous system. J Comp Neurol. 2005;487(2):190-203.

  36. Vega González MT, Peña Ortiz J, Ramos Garibay A, Llergo Valdez R. Penfigoide ampolloso asociado con carcinoma epidermoide de pene. Comunicación de un caso y revisión bibliográfica. Dermatología Rev Mex. 2009;53:100-5.




2020     |     www.medigraphic.com